|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Des Jarlais G, Kaplan CP, Haas JS,
Gregorich SE, Pérez-Stable EJ and Kerlikowske K: Factors affecting
participation in a breast cancer risk reduction telephone survey
among women from four racial/ethnic groups. Prev Med. 41:720–727.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Salehi F, Dunfield L, Phillips KP, Krewski
D and Vanderhyden BC: Risk factors for ovarian cancer: An overview
with emphasis on hormonal factors. J Toxicol Environ Health B Crit
Rev. 11:301–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vo C and Carney ME: Ovarian cancer
hormonal and environmental risk effect. Obstet Gynecol Clin North
Am. 34:687–700. viii2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xie Y, Zhu J, Zhou XJ, Chen J, Lu NH and
Wang CW: Expression of peroxisome proliferators-activated
receptor-gamma and cyclooxygenase-2 in Helicobacter pylori
infection-associated diseases and significance thereof. Zhonghua Yi
Xue Za Zhi. 86:2683–2689. 2006.In Chinese.
|
|
6
|
DuBois RN, Gupta R, Brockman J, Reddy BS,
Krakow SL and Lazar MA: The nuclear eicosanoid receptor, PPARgamma,
is aberrantly expressed in colonic cancers. Carcinogenesis.
19:49–53. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang WG, Redfern A, Bryce RP and Mansel
RE: Peroxisome proliferator activated receptor-gamma (PPAR-gamma)
mediates the action of gamma linolenic acid in breast cancer cells.
Prostaglandins Leukot Essent Fatty Acids. 62:119–127. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wijnhoven BP, Lindstedt EW, Abbou M,
Ijzendoorn Y, de Krijger RR, Tilanus HW and Dinjens WN; Rotterdam
Esophageal Tumor Study Group: Molecular genetic analysis of the von
Hippel-Lindau and human peroxisome proliferator-activated receptor
gamma tumor-suppressor genes in adenocarcinomas of the
gastroesophageal junction. Int J Cancer. 94:891–895. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang TH and Szabo E: Induction of
differentiation and apoptosis by ligands of peroxisome
proliferator-activated receptor gamma in non-small cell lung
cancer. Cancer Res. 60:1129–1138. 2000.PubMed/NCBI
|
|
10
|
Papi A, De Carolis S, Bertoni S, Storci G,
Sceberras V, Santini D, Ceccarelli C, Taffurelli M, Orlandi M and
Bonafé M: PPARγ and RXR ligands disrupt the inflammatory cross-talk
in the hypoxic breast cancer stem cells niche. J Cell Physiol.
229:1595–1606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chatterjee A, Kusunoki H, Taniyama Y,
Rakugi H and Morishita R: Improvement of metabolic syndrome by
irbesartan via the PPARγ/HGF pathway in apolipoprotein E knockout
mice. Biomed Rep. 1:65–70. 2013.PubMed/NCBI
|
|
12
|
Łukaszewicz-Zając M, Mroczko B,
Guzińska-Ustymowicz K, Pryczynicz A, Gryko M, Kemona A, Kędra B and
Szmitkowski M: Matrix metalloproteinase 2 (MMP-2) and their tissue
inhibitor 2 (TIMP-2) in gastric cancer patients. Adv Med Sci.
58:235–243. 2013. View Article : Google Scholar
|
|
13
|
Waite LL, Louie RE and Taylor RN:
Circulating activators of peroxisome proliferator-activated
receptors are reduced in preeclamptic pregnancy. J Clin Endocrinol
Metab. 90:620–626. 2005. View Article : Google Scholar
|
|
14
|
Liu J, Lu H, Huang R, Lin D, Wu X, Lin Q,
Wu X, Zheng J, Pan X, Peng J, et al: Peroxisome proliferator
activated receptor-gamma ligands induced cell growth inhibition and
its influence on matrix metalloproteinase activity in human myeloid
leukemia cells. Cancer Chemother Pharmacol. 56:400–408. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Balakumar P, Bishnoi HK and Mahadevan N:
Telmisartan in the management of diabetic nephropathy: A
contemporary view. Curr Diabetes Rev. 8:183–190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takagi H, Mizuno Y, Yamamoto H, Goto SN
and Umemoto T; All-Literature Investigation of Cardiovascular
Evidence Group: Effects of telmisartan therapy on interleukin-6 and
tumor necrosis factor-alpha levels: A meta-analysis of randomized
controlled trials. Hypertens Res. 36:368–373. 2013. View Article : Google Scholar
|
|
17
|
Lacourcière Y: Telmisartan or valsartan
alone or in combination with hydrochlorothiazide: A review. Clin
Exp Hypertens. 35:50–60. 2013. View Article : Google Scholar
|
|
18
|
Maejima Y, Okada H, Haraguchi G, Onai Y,
Kosuge H, Suzuki J and Isobe M: Telmisartan, a unique ARB, improves
left ventricular remodeling of infarcted heart by activating PPAR
gamma. Lab Invest. 91:932–944. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li J, Chen L, Yu P, Liu B, Zhu J and Yang
Y: Telmisartan exerts anti-tumor effects by activating peroxisome
proliferator-activated receptor-γ in human lung adenocarcinoma A549
cells. Molecules. 19:2862–2876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shi M, Cao M, Song J, Liu Q, Li H, Meng F,
Pan Z, Bai J and Zheng J: PinX1 inhibits the invasion and
metastasis of human breast cancer via suppressing NF-κB/MMP-9
signaling pathway. Mol Cancer. 14:662015. View Article : Google Scholar
|
|
21
|
Mozzetti S, Ferlini C, Concolino P,
Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E,
Ranelletti FO, Ferrandina G and Scambia G: Class III beta-tubulin
overexpression is a prominent mechanism of paclitaxel resistance in
ovarian cancer patients. Clin Cancer Res. 11:298–305.
2005.PubMed/NCBI
|
|
22
|
Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han
LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, et
al: Metronomic chemotherapy enhances the efficacy of antivascular
therapy in ovarian cancer. Cancer Res. 67:281–288. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Araújo Júnior RF, Leitão Oliveira AL,
de Melo Silveira RF, de Oliveira Rocha HA, de França Cavalcanti P
and de Araújo AA: Telmisartan induces apoptosis and regulates Bcl-2
in human renal cancer cells. Exp Biol Med (Maywood). 240:34–44.
2015. View Article : Google Scholar
|
|
24
|
Koyama N, Nishida Y, Ishii T, Yoshida T,
Furukawa Y and Narahara H: Telmisartan induces growth inhibition,
DNA double-strand breaks and apoptosis in human endometrial cancer
cells. PLoS One. 9:e930502014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Auwerx J: PPARgamma, the ultimate thrifty
gene. Diabetologia. 42:1033–1049. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Komar CM: Peroxisome
proliferator-activated receptors (PPARs) and ovarian
function-implications for regulating steroidogenesis,
differentiation and tissue remodeling. Reprod Biol Endocrinol.
3:412005. View Article : Google Scholar
|
|
27
|
Kolli V, Stechschulte LA, Dowling AR,
Rahman S, Czernik PJ and Lecka-Czernik B: Partial agonist,
telmisartan, maintains PPARγ serine 112 phosphorylation, and does
not affect osteoblast differentiation and bone mass. PLoS One.
9:e963232014. View Article : Google Scholar
|
|
28
|
Pang T, Sun LX, Wang T, Jiang ZZ, Liao H
and Zhang LY: Telmisartan protects central neurons against nutrient
deprivation-induced apoptosis in vitro through activation of PPARγ
and the Akt/GSK-3 β pathway. Acta Pharmacol Sin. 35:727–737. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yiqin Y, Meilin X, Jie X and Keping Z:
Aspirin inhibits MMP-2 and MMP-9 expression and activity through
PPARalpha/gamma and TIMP-1-mediated mechanisms in cultured mouse
celiac macrophages. Inflammation. 32:233–241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Funao K, Matsuyama M, Kawahito Y, Sano H,
Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan as
a peroxisome proliferator-activated receptor-γ ligand is a new
target in the treatment of human renal cell carcinoma. Mol Med Rep.
2:193–198. 2009.PubMed/NCBI
|
|
31
|
Zafiriou S, Stanners SR, Saad S, Polhill
TS, Poronnik P and Pollock CA: Pioglitazone inhibits cell growth
and reduces matrix production in human kidney fibroblasts. J Am Soc
Nephrol. 16:638–645. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Araújo AA, Souza TO, Moura LM, Brito GA,
Aragão KS, Araújo LS, Medeiros CA, Alves MS and Araújo RF Jr:
Effect of telmisartan on levels of IL-1, TNF-α, down-regulated
COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis
model. J Clin Periodontol. 40:1104–1111. 2013. View Article : Google Scholar
|
|
33
|
Yokota T, Osanai T, Hanada K, Kushibiki M,
Abe N, Oikawa K, Tomita H, Higuma T, Yokoyama J, Hanada H and
Okumura K: Effects of telmisartan on markers of ventricular
remodeling in patients with acute myocardial infarction: Comparison
with enalapril. Heart Vessels. 25:460–468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu J, Lin H, Liu D, Liu J, Wang N, Mei X,
Sun J, Yang G and Zhang X: The protective effect of telmisartan in
Type 2 diabetes rat kidneys is related to the downregulation of
thioredoxin-interacting protein. J Endocrinol Invest. 36:453–459.
2013.
|
